Selective inhibition of the membrane attack complex of complement by low molecular weight components of the aurin tricarboxylic acid synthetic complex

Neurobiology of Aging

Volumn 33, Issue 10, 2012, Pages 2237-2246

  Lee, Moonhee ^a   Guo, Jian Ping ^a   Schwab, Claudia ^a   McGeer, Edith G ^a   McGeer, Patrick L ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Alzheimer's disease; C5b 9; Complement C9 protein; Macular degeneration; Paroxysmal nocturnal hemoglobinuria

Indexed keywords

AURIN HEXACARBOXYLIC ACID; AURIN QUADRACARBOXYLIC ACID; AURINTRICARBOXYLIC ACID; CARBOXYLIC ACID; COMPLEMENT C5B 8; COMPLEMENT COMPONENT C5B; COMPLEMENT COMPONENT C9; COMPLEMENT MEMBRANE ATTACK COMPLEX; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPLEX FORMATION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG STRUCTURE; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMOLYSIS; HUMAN; HUMAN CELL; IC 50; MOLECULAR DYNAMICS; MOLECULAR WEIGHT; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; WESTERN BLOTTING;

ALZHEIMER DISEASE; ANIMALS; AURINTRICARBOXYLIC ACID; BYSTANDER EFFECT; COMPLEMENT SYSTEM PROTEINS; HEMOLYSIS; HUMANS; MEMORY; MICE; MICE, TRANSGENIC; RATS; SALICYLATES;

EID: 84861739864     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2011.12.005     Document Type: Article

References (49)

1. Anderson D.H., Mullins R.F., Hageman G.S., Johnson L.V. A role for local inflammation in the formation of drusen in the aging eye. Am. J. Ophthalmol 2002, 134:411-431.
2. Anderson D.H., Radeke M.J., Gallo N.B., Chapin E.A., Johnson P.T., Curletti C.R., Hancox L.S., Hu J., Ebright J.N., Malek G., Hauser M.A., Rickman C.B., Bok D., Hageman G.S., Johnson L.V. The pivotal role of the complement system in aging and age-related macular degeneration: hypothesis re-visited. Prog. Retin. Eye Res 2010, 29:95-112.
3. Bonifati D.M., Kishore U. Role of complement in neurodegeneration and neuroinflammation. Mol. Immunol 2007, 44:999-1010.
4. Cushman M., Kanamathareddy S. Synthesis of the covalent hydrate of the incorrectly assumed structure of Aurintricarboxylic acid (ATA). Tetrahedron 1990, 46:1491-1498.
5. Cushman M., Wang P., Stowell J.G., Schols D., De Clercq E. Structural investigation and anti-HIV activities of high molecular weight ATA polymers. J. Org. Chem 1992, 57:7241-7248.
6. Cushman M., Kanamathareddy S., De Clercq E., Schols D., Goldman M.E., Bowen J.A. Synthesis and anti-HIV activities of low molecular weight aurintricarboxylic acid fragments and related compounds. J. Med. Chem 1991, 34:337-342.
7. Eikelenboom P., Stam F.C. Immunoglobulins and complement factors in senile plaques: an immunoperoxidase study. Acta Neuropathol 1982, 57:239-242.
8. González R.G., Blackburn B.J., Schleich T. Fractionation and structural elucidation of the active components of aurintricarboxylic acid, a potent inhibitor of protein nucleic acid interactions. Biochim. Biophys. Acta 1979, 562:534-545.
9. Heisig G.B., Lauer M. Ammonium salt of aurin tricarboxylic acid. Org. Synth 1941, 1:54.
10. Hillmen P., Young N.S., Schubert J., Brodsky R.A., Socié G., Muus P., Röth A., Szer J., Elebute M.O., Nakamura R., Browne P., Risitano A.M., Hill A., Schrezenmeier H., Fu C.L., Maciejewski J., Rollins S.A., Mojcik C.F., Rother R.P., Luzzatto L. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J. Med 2006, 355:1233-1243.
11. Holmes C., Boche D., Wilkinson D., Yadegarfar G., Hopkins V., Bayer A., Jones R.W., Bullock R., Love S., Neal J.W., Zotova E., Nicoll J.A. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet 2008, 372:216-223.
12. Hüsler T., Lockert D.H., Kaufman K.M., Sodetz J.M., Sims P.J. Chimeras of human complement C9 reveal the site recognized by complement regulatory protein CD59. J. Biol. Chem 1995, 270:3483-3486.
13. Joseph R., Tsang W., Han E., Saed G.M. Neuronal beta-amyloid precursor protein gene expression: regulation by aurintricarboxylic acid. Brain Res 1993, 625:244-255.
14. Kawamata T., Akiyama H., Yamada T., McGeer P.L. Immunologic reactions in amyotrophic lateral sclerosis. Am. J. Pathol 1992, 140:697-707.
15. Kira R., Ihara K., Takada H., Gondo K., Hara T. Nonsense mutation in exon 4 of human complement C9 gene is the major cause of Japanese complement C9 deficiency. Hum. Genet 1998, 102:605-610.
16. Kojima T., Horiuchi T., Nishizaka H., Fukumori Y., Amano T., Nagasawa K., Niho Y., Hayashi K. Genetic basis of human complement C8 alpha-gamma deficiency. J. Immunol 1998, 161:3762-3766.
17. Lee M., Schwab C., McGeer P.L. Astrocytes are GABAergic cells that modulate microglial activity. Glia 2011, 59:152-165.
18. Matsuno H., Kozawa O., Niwa M., Tanabe K., Ichimaru K., Takiguchi Y., Yokota M., Hayashi H., Uematsu T. Multiple inhibition of platelet activation by aurintricarboxylic acid prevents vascular stenosis after endothelial injury in hamster carotid artery. Thromb. Haemost 1998, 79:865-871.
19. McGeer P.L., Akiyama H., Itagaki S., McGeer E.G. Activation of the classical complement pathway in brain tissue of Alzheimer patients. Neurosci. Lett 1989, 107:341-346.
20. McGeer P.L., McGeer E. Is there a future for vaccination as a treatment for Alzheimer's disease?. Neurobiol. Aging 2003, 24:391-395.
21. McGeer P.L., McGeer E.G. Inflammation and the degenerative diseases of aging. Ann. N. Y. Acad. Sci 2004, 1035:104-116.
22. Miklossy J., Martins L., Darbinian N., Khalili K., McGeer P.L. Type 2 diabetes: local inflammation and direct effect of bacterial toxic components. The Open Path. J 2008, 2:86-95.
23. Moran P.M., Higgins L.S., Cordell B., Moser P.C. Age-related learning deficits in transgenic mice expressing the 751-amino acid isoform of human β-amyloid precursor protein. Proc. Natl. Acad. Sci. U. S. A. 1995, 92:5341-5345.
24. Nakashima S., Qian Z., Rahimi S., Wasowska B.A., Baldwin W.M. Membrane attack complex contributes to destruction of vascular integrity in acute lung allograft rejection. J. Immunol 2002, 169:4620-4627.
25. Nicoll J.A., Wilkinson D., Holmes C., Steart P., Markham H., Weller R.O. Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report. Nat. Med 2003, 9:448-452.
26. Oakley H., Cole S.L., Logan S., Maus E., Shao P., Craft J., Guillozet-Bongaarts A., Ohno M., Disterhoft J., Van Eldik L., Berry R., Vassar R. Intraneuronal beta amyloid aggregates, neurodegeneration, and neuron loss in transgenic mice with five familial Alzheimer's disease mutations: potential factors in amyloid plaque formation. J. Neurosci 2006, 26:10129-10140.
27. Orgogozo J.M., Gilman S., Dartigues J.F., Laurent B., Puel M., Kirby L.C., Jouanny P., Dubois B., Eisner L., Flitman S., Michel B.F., Boada M., Frank A., Hock C. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology 2003, 61:46-54.
28. Owens M.R., Holme S. Aurin tricarboxylic acid inhibits adhesion of platelets to subendothelium. Thromb. Res 1996, 81:177-185.
29. Parham K.L., Roberts A., Thomas A., Würzner R., Henderson H.E., Potter P.C., Morgan B.P., Orren A. Prevalence of mutations leading to complete C6 deficiency (C6Q0) in the Western Cape, South Africa and detection of novel mutations leading to C6Q0 in an Irish family. Mol. Immunol 2007, 44:2756-2760.
30. Rameix-Welti M.A., Régnier C.H., Bienaimé F., Blouin J., Schifferli J., Fridman W.H., Sautès-Fridman C., Frémeaux-Bacchi V. Hereditary complement C7 deficiency in nine families: subtotal C7 deficiency revisited. Eur. J. Immunol 2007, 37:1377-1385.
31. Regan R.F., Panter S.S., Witz A., Tilly J.L., Giffard R.G. Ultrastructure of excitotoxic neuronal death in murine cortical culture. Brain Res 1995, 705:188-198.
32. Ricklin D., Hajishengallis G., Yang K., Lambris J.D. Complement: a key system for immune surveillance and homeostasis. Nat. Immunol 2010, 11:785-797.
33. Rogers J., Coopers N.R., Webster S., Schultz J., McGeer P.L., Styren S.D., Civin W.H., Brachova L., Brad B., Wardi P., Lieberburg I. Complement activation by β-amyloid in Alzheimer disease. Proc. Natl. Acad. Sci. U. S. A. 1992, 89:10016-10020.
34. Schenk D., Barbour R., Dunn W., Gordon G., Grajeda H., Guido T., Hu K., Huang J., Johnson-Wood K., Khan K., Kholodenko D., Lee M., Liao Z., Lieberburg I., Motter R., Mutter L., Soriano F., Shopp G., Vasquez N., Vandevert C., Walker S., Wogulis M., Yednock T., Games D., Seubert P. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature 1999, 400:173-177.
35. Schmiedt W., Kinscherf R., Deigner H.P., Kamencic H., Nauen O., Kilo J., Oelert H., Metz J., Bhakdi S. Complement C6 deficiency protects against diet-induced atherosclerosis in rabbits. Arterio Thromb. Vas Biol 1998, 18:1790-1795.
36. Schwab C., Hosokawa M., McGeer P.L. Transgenic mice overexpressing amyloid beta protein are an incomplete model of Alzheimer disease. Exp. Neurol 2004, 182:52-64.
37. Schwab C., Steele J.C., McGeer P.L. Neurofibrillary tangles of Guam parkinson-dementia are associated with reactive microglia and complement proteins. Brain Res 1996, 707:196-205.
38. Shen Y., Lue L., Yang L., Roher A., Kuo Y., Strohmeyer R., Goux W.J., Lee V., Johnson G.V., Webster S.D., Cooper N.R., Bradt B., Rogers J. Complement activation by neurofibrillary tangles in Alzheimer's disease. Neurosci. Lett 2001, 305:165-168.
39. Takeda J., Miyata T., Kawagoe K., Iida Y., Endo Y., Fujita T., Takahashi M., Kitani T., Kinoshita T. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell 1993, 73:703-711.
40. Veerhuis R., Nielsen H.M., Tenner A.J. Complement in the brain. Mol. Immunol 2011, 48:1592-1603.
41. Wang P., Kozlowski J., Cushman M. Isolation and structural elucidation of low molecular weight components of aurintricarboxylic acid (ATA). J. Org. Chem 1992, 57:3861-3866.
42. Wu G., Hu W., Shahsafaei A., Song W., Dobarro M., Sukhova G.K., Bronson R.R., Shi G.P., Rother R.P., Halperin J.A., Qin X. Complement regulator CD59 protects against atherosclerosis by restricting the formation of complement membrane attack complex. Circ. Res 2009, 104:550-558.
43. Wu G., Korsgren O., Sun S., Van Rooijen N., Tibell A. Effect of plasma exchange in combination with deoxyspergualin on the survival of guinea-pig hearts in macrophage-depleted C6-deficient rats. Xenotransplantation 2003, 10:214-222.
44. Wyss-Coray T., Yan F., Lin A.H., Lambris J.D., Alexander J.J., Quigg R.J., Masliah E. Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice. Proc. Natl. Acad. Sci. U. S. A. 2002, 99:10837-10842.
45. Yamada T., McGeer P.L., McGeer E.G. Lewy bodies in Parkinson's disease are recognized by antibodies to complement proteins. Acta Neuropathol 1992, 84:101-104.
46. Yamashina M., Ueda E., Kinoshita T., Takami T., Ojima A., Ono H., Tanaka H., Kondo N., Orii T., Okada N., Okada H., Inoue K., Kitani T. Inherited complete deficiency of 20-kilodalton homologous restriction factor (CD59) as a cause of paroxysmal nocturnal hemoglobinuria. N Engl J. Med 1990, 323:1184-1189.
47. Yasojima K., Schwab C., McGeer E.G., McGeer P.L. Generation of C-reactive protein and complement components in atherosclerotic plaques. Am. J. Pathol 2001, 158:1039-1051.
48. Yasuhara O., Aimy Y., McGeer E.G., McGeer P.L. Expression of the membrane attack complex in Pick disease brain. Brain Res 1994, 654:346-349.
49. Zhu Z.B., Totemchokchyakarn K., Atkinson T.P., Volanakis J.E. Molecular defects leading to human complement component C6 deficiency in an African-American family. Clin. Exp. Immunol 1998, 111:91-96.